BEAT - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Physician Researcher to Board of Directors
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors: Michael R. Jaff, DO. This appointment brings the number of board members to eight. A renowned vascular physician and researcher, Jaff has an impressive background in the clinical and industry space. He will add “a unique and extremely valuable perspective that is crucial for HeartBeam as we progress toward our initial clearances and the commercial availability of our technology,” the announcement stated. Currently the chief medical officer and vice president of Clinical Affairs, Technology and Innovation of the Peripheral Interventions division at Boston Scientific Corporation, Jaff has also been a professor of medicine at Harvard Medical School, president of Newton-Wellesley Hospital, and the inaugural Paul and Phyllis Fireman endowed chair of vascular medicine and medical director of the Fireman Vascular Center at the Massachusetts General Hospital. A recognized expert in vascular medicine, he founded VasCore, the Vascular Ultrasound Core Laboratory, and is the author of more than 300 peer-reviewed publications and 10 textbooks. “Dr. Jaff brings an extraordinary level of expertise to the HeartBeam board, with his extensive experience as a researcher, practicing clinician, hospital administrator and industry executive,” said HeartBeam executive chair Rich Ferrari in the press release. “His tremendous knowledge in clinical trial design and execution, as well as his experience supporting novel technologies in front of the Food and Drug Administration, will be valuable for the company.”
To view the full press release, visit https://ibn.fm/B8igm
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.